Claude H. Nash, PhD
Chief Executive Officer and Chairman

Paul J. Leibowitz, PhD
Chief Technology Officer and Director

Julian M.E. Lee, MA (Cantab), ACA
Chief Financial Officer and Director

Sandra Panem, PhD
Director

Robert J. Powell, Ph.D., MBA
Vice President, University Liaison

Eric R. Leibowitz, Esq.
In-House Counsel



Francis J. Bullock, PhD

Gerald Malone, MA, LLB

Seth A. Rudnick, MD

Natalie S. Rudolph, PhD



Bingham McCutchen LLP
US corporate counsel

Fasken Martineau LLP
UK corporate counsel

Dr. Rudolph is a geneticist who draws on more than 17 years of experience in management support for research and development programs in the biotechnology and biomedical industries.

In the late 1980s and early 1990s, Dr. Rudolph was involved in the early stages of two start-up biotechnology companies. At Viomedics, she established product development, testing and technical support for a line of chromogenic and fluorescent biomedical assay reagents. Subsequently, Dr. Rudolph became the third scientist to join Transgenic Sciences, Inc., a start-up biotechnology company which became the R&D Division of TSI Corporation and later was divested to Exemplar Corporation. At TSI, she helped develop and launch the company’s first two research products; managed intellectual property portfolios; coordinated technology licensing and extramural research collaborations; developed research strategies, competitive profiles, timelines and financial models for development programs and potential acquisitions; and packaged successful research grant applications worth more than $1-million in federal funding.

For the last decade, Dr. Rudolph has operated a successful consulting practice that offers services such as competitive analysis, R&D program planning, research grant proposals and technical writing for small companies and academic research centers. These projects have addressed emerging technologies in areas such as cellular, animal and human genetics, immunogenetics, genomics and proteomics, tissue engineering, drug and vaccine delivery, genetic toxicology, mammalian cloning and transgenics and medical devices. Dr. Rudolph has written winning research proposals worth more than $15-million in federal research funding for her clients. Some of these proposals involved corporate/academic research collaborations, and benefited from Dr. Rudolph’s familiarity with both the corporate and academic research cultures.

Dr. Rudolph received master’s and doctorate degrees from the Department of Genetics at the University of Wisconsin – Madison, where she studied biochemical and population genetics and biomedical ethics. She completed postdoctoral training in cell and molecular genetics at the University of Rochester Medical School and Harvard Medical School.